Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
LPA receptor antagonists and agonists act on receptors for the lipid mediator lysophosphatidic acid (LPA). Six LPA receptors, LPA1 to LPA6, are known, and all belong to the G protein-coupled receptor family. The first, LPA1, was identified in 1996 as the product of ventricular zone gene-1 in the developing cerebral cortex. LPA signaling controls cell migration, proliferation and cytoskeletal change in many tissues. In 2008 LPA1 was linked to fibroblast recruitment and vascular leak in a model of pulmonary fibrosis. Ki16425 and Ki16198 block LPA1 and LPA3, and AM966, AM095 and ONO-7300243 are LPA1 antagonists. GRI 977143 and Radioprotectin-1 act as LPA2 agonists, while AS2717638 antagonizes LPA5.
TAK-615 is a negative allosteric modulator (NAM) of the lysophosphatidic acid receptor 1 (LPA1). It exhibits high-affinity binding with a Kd of 1.7 nM, along with a lower affinity of 14.5 nM. This compound is primarily used in research focused on pulmonary fibrosis, enabling investigations into the role of LPA1 in fibrotic pathways and potential therapeutic interventions.
Synonyms: N-Palmitoyl-tyrosine phosphoric acid ammonium
N-PTyrosine PA ammonium is a lysophosphatidic acid (LPA) receptor modulator that functions primarily as a competitive inhibitor at LPA1 and a partial agonist at LPA5. This compound may inhibit LPA receptor activation and downstream signaling pathways by competing for binding sites with native agonists. Additionally, N-PTyrosine PA ammonium is capable of inducing morphological changes and promoting aggregation, as well as preventing LPA-induced morphological alterations through prior receptor desensitization. Its applications extend to the study of various conditions, including atherosclerosis and acute ischemic syndromes, such as unstable angina and myocardial infarction.
Out of stock
All 3 sizes